URBAN ARCH Russia Cohort

Grant Title: URBAN ARCH (4/5) Russia Cohort – Targeting HIV-Comorbidities With Pharmacotherapy To Reduce Alcohol and Tobacco Use In HIV-Infected Russians

The Studying Partial-agonists for Ethanol and Tobacco Elimination in Russians with HIV (St PETER HIV) study will continue to follow and expand (from 250 to 400 participants) the existing Russia Cohort in order to compare the effects of varenicline, cytisine, and nicotine replacement therapy (NRT) to reduce: 1) alcohol use and craving, 2) smoking; and 3) inflammation and risk for CHD and mortality. Randomized control trial arms will be: 1) Varenicline + NRT placebo; 2) Varenicline placebo + NRT; 3) Cytisine + NRT placebo; and 4) Cytisine placebo + NRT.

Principal Investigators:

Matthew Freiberg, MD, MSc
Director, Vanderbilt Center for Clinical Cardiovascular outcomes REsearch And Trials Evaluation (V-C3REATE)
Associate Professor of Medicine, Vanderbilt University Medical Center

Jeffrey Samet, MD, MA, MPH
Chief of Section of General Internal Medicine, BMC
Professor of Medicine and Public Health, Boston University Schools of Public Health and Medicine (BUSPH/BUSM)

Hilary Tindle, MD, MPH
Associate Professor of Medicine, Vanderbilt University
Founding Director of ViTAL, the Vanderbilt Center for Tobacco, Addiction and Lifestyle

Study Contact:

Natalia Gnatienko, MPH (natalia.gnatienko@bmc.org)
Lead Research Project Manager

Study Staff:

Sally Bendiks, MPH 
Research Coordinator, Boston Medical Center

Sarah Loch, MPH, CPH 
Research Programs Manager, Vanderbilt University Medical Center

Tatiana Yaroslavtseva, MD
Scientific Secretary, Valdman Institute of Pharmacology

Study Investigators:

Elena Blokhina, MD, PhD
Deputy Director, Valdman Institute of Pharmacology, First St. Petersburg Pavlov State Medical University

Evgeny Krupitsky, MD, PhD
Chief, Lab of Clinical Pharmacology of Addictions, Pavlov State Medical University (PSMU)
Chief, Department of Addictions, St. Petersburg Bekhterev Psychoneurological Research Institute

Dmitry Lioznov, MD, PhD
Vice-Rector of Nursing Education and Head of Center for Preventive Medicine, PSMU

Michael Stein, MD
Professor and Chair of the Department of Health Law, Policy & Management, BUSPH

Edwin Zvartau, MD, PhD
Head of Department of Clinical Pharmacology & Evidence-Based Med and Research Director of Valdman Institute of Pharmacology, PSMU

Study progress: The St PETER HIV study is expected to begin participant recruitment and assessments in 2017. For more information, click here.

Recruitment Site: St. Petersburg Pavlov State Medical University, St. Petersburg, Russia

First Cycle (2011-2016) Original Russia Cohort Grant Title: Alcohol & Zinc Impact on Inflammatory Markers in HIV Disease

The original Russian Cohort aimed to assess the longitudinal association between alcohol consumption and biomarkers of microbial translocation (sCD14) and inflammation/altered coagulation (D-dimer) in a cohort of HIV-infected drinkers in St. Petersburg, Russia. (Russian summary)
ClinicalTrials.gov

Affiliated Studies:

Zinc for HIV Disease Among Alcohol Users – An RCT in the Russia ARCH Cohort

Pilot Study of Opioid-Receptor Antagonists to Reduce Pain and Inflammation Among HIV-Infected Persons with Alcohol Problems

St. PETER HIV-Alcohol, Protein Biomarkers and Cardiovascular Disease Risk

1/2 Alcohol Associated Comorbidities and Microbiome Evaluation in HIV (ACME HIV)

Click here for additional information about the original Russia Cohort and here for more information about ZINC HIV RCT. Click here to see baseline characteristics.